Evaluating oncology drugs in patient tumors with preserved native tumor microenvironment
Despite advances in both 3D in vitro human cell-based models and in vivo animal models, 97% of oncology drugs that enter clinical trials fail to receive regulatory approval. Patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors are therefore required to:
- Understand drug effects on native tumor microenvironment (TME)
- Gain more accurate insights beyond general cell viability
- Evaluate immuno-oncology drugs including immune checkpoint inhibitors in a non-artificial setting
- Make better informed decisions about progressing into the clinic with more data
In this webinar, Dr. Nataliia Beztsinna reviews the benefits of a novel 3D Ex Vivo Patient Tissue Platform that uses freshly collected patient tumor material and phenotypic high-content imaging analysis to evaluate preclinical drug candidates in a high-throughput format.
Attendees of this webinar will learn how to:
- Evaluate effects of immunotherapies, including ICIs, with endogenous immune cells or autologous TILs/PBMCs
- Accurately measure tumor killing, immune cell proliferation, migration, and infiltration
- Assess single and combination treatments in high throughput
- Obtain more data to better inform the progression of drug candidates into the clinic
Who should attend:
- Medical oncologists, pathologists, and immuno-oncology researchers
- Scientists from pharma, biotech, and academia who work in the field of pre-clinical drug development. Decision makers who want to explore opportunities to reduce the use of animal models.